Table 1

Model for Assessing Human Papillomavirus Vaccination Strategies

Elamin H. Elbasha*

, Erik J. Dasbach*, and Ralph P. Insinga*

Author affiliations: *Merck Research Laboratories, North Wales, Pennsylvania, USA;

Cost-effectiveness analysis of alternative HPV vaccination strategies*

	Discounted total		Incremental
Strategy	Costs	QALY	Costs	QALY	$/QALY†
No vaccination	72,659,302	2,698,711	––	––	––
12-y-old girls	74,042,990	2,699,178	1,383,687	467	2,964
12-y-old girls and boys	78,707,825	2,699,327	4,664,835	149	Dominated
12-y-old girls plus 12- to 24-y-old females catch-up	74,815,667	2,699,343	–3,892,159	16	4,666
12-y-old girls and boys plus 12− to 24-y-old females catch-up	79,746,357	2,699,461	4,930,690	118	41,803
12-y-old girls and boys plus 12− to 24-y-old females and males catch-up	81,761,210	2,699,506	2,014,853	45	45,056

*Assumes cost of vaccination series is US $360 and duration of protection is lifelong. All costs are measured in 2005 US dollars, and costs and QALY are discounted at 3%. HPV, human papillomavirus; QALY, quality-adjusted life years.
†Compared with the preceding nondominated strategy. Strategy A is dominated if there is another strategy, B, that is more effective and less costly than strategy A.

Main Article

Page created: June 28, 2010

Page updated: June 28, 2010

Page reviewed: June 28, 2010

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.